Fred Hardwicke
Medical Oncology · Childress, TXNPI 1194713248
Payments from drug & device makers
Across 88 payments — averaging $34.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Seagen Inc.$257
- AbbVie$242
- Merck$199
- Exelixis Inc.$171
- Astellas Pharma US Inc$151
- plus $878 from 20 others
What the payments were for
- Food & beverage$1,67183%
- Education$34017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $1,113 |
| Seagen Inc. | 5 | $257 |
| AbbVie | 6 | $242 |
| Merck | 11 | $199 |
| Exelixis Inc. | 5 | $171 |
| Astellas Pharma US Inc | 4 | $151 |
| E.r. Squibb & Sons, L.L.C. | 10 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Novartis | 5 | $99 |
| Genentech USA, Inc. | 5 | $86 |
| Pfizer | 4 | $64 |
| Bristol Myers Squibb | 3 | $62 |
| AstraZeneca(2 entities) | 2 | $61 |
| Gilead | 3 | $46 |
| Tersera Therapeutics LLC | 2 | $37 |
| Bayer | 2 | $32 |
| Eisai Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Sanofi | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Array Biopharma Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,011 in reported general payments places this provider in the 25th percentile of 495 medical oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 34 | $596,724 |
| NinlaroIxazomib Citrate | 15 | $292,511 |
| RevlimidLenalidomide | 11 | $196,190 |
| EliquisApixaban | 14 | $8,049 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $2,019 |
| Hydromorphone Hcl | 12 | $414 |
| Tamoxifen Citrate | 22 | $404 |
| Dexamethasone | 16 | $382 |
| Ondansetron OdtOndansetron | 11 | $296 |
| Levothyroxine Sodium | 37 | $206 |
| Raloxifene Hcl | 12 | $172 |
| Hydroxyzine Hcl | 12 | $116 |
| Letrozole | 19 | $108 |
| Acyclovir | 13 | $108 |
| Promethazine Hcl | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $596,72434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $102 | $292,51115 claims |
| Bristol Myers SquibbRevlimid | $62 | $196,19011 claims |
| PfizerEliquis | $64 | $8,04914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Childress
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Sawsan RashdanDallas$29.9M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.